OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
93
Results
Show all
Save search
Copy query
Show results for
Unknown
(93)
Publication Date
Release Date
2021
(21)
2022
(14)
2018
(11)
2025
(10)
2019
(9)
2024
(8)
2023
(5)
2020
(5)
2017
(5)
2016
(2)
2010
(2)
2011
(1)
Previous
page
1 / 10
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
10
Next
page
Sort
by:
Relevance
Page size
10
Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.
Not available
S-EPMC11573082
|
biostudies-literature
Cite
Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of
18
F-FDG-PET.
Not available
S-EPMC10828178
|
biostudies-literature
Cite
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591
|
biostudies-literature
Cite
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
Not available
S-EPMC9779650
|
biostudies-literature
Cite
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.
Not available
S-EPMC8548918
|
biostudies-literature
Cite
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031
|
biostudies-literature
Cite
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536
|
biostudies-literature
Cite
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867
|
biostudies-literature
Cite
Previous
page
1 / 10
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
10
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets